Safety and Immunogenicity of COVID-19 Vaccine Booster in Patients With Liver Diseases

Summary

Previous studies should that patients with chronic liver diseases, cirrhosis, hepatocellular carcinoma and post-liver-trasplant status had lower immunological response to SARS-CoV-2 vaccines than healthy population. Along with the waning of antibody and emerging SARS-CoV-2 variants, a third dose SARS-CoV-2 booster vaccination is now considered as an effective strategy. Previous studies showed good safety and immunogenicity of the SARS-CoV-2 booster vaccination in healthy population. However, the relevant information in patients with liver diseases need further research. This study (NMCID-CHESS 2201) aimed to investigate the safety and immunogenicity of the SARS-CoV-2 booster vaccination in population with chronic liver diseases

Conditions

• COVID-19
• Vaccine Reaction
• Liver Diseases

Sponsors & Collaborators

• LanZhou University

  collaborator OTHER

• Xingtai People's Hospital

  collaborator OTHER

• The Third Central Hospital of Tianjin

  collaborator UNKNOWN

• The Third People's Hospital of Taiyuan

  collaborator OTHER

• Lishui Country People's Hospital

  collaborator OTHER

• Baoding People's Hospital

  collaborator UNKNOWN

• The Affiliated Hospital of Qingdao University

  collaborator OTHER

• Affiliated Hospital of Nanjing University of Chinese Medicine

  collaborator OTHER

• The Fifth People's Hospital of Wuxi

  collaborator UNKNOWN

• Jincheng People's Hospital

  collaborator OTHER

• The Sixth Peoples Hospital of Shenyang

  collaborator UNKNOWN

• Zhenjiang Third Hospital

  collaborator UNKNOWN

• The Third People's Hospital of Linfen City

  collaborator UNKNOWN

• The First Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• The Fourth People's Hospital of Qinghai Province

  collaborator OTHER

• The Third People's Hospital of Tibet Autonomous Region

  collaborator UNKNOWN

• The Second Affiliated Hospital of Chongqing Medical University

  collaborator OTHER

• Peking University Health Science Center

  collaborator OTHER

• The Affiliated Hospital Of Southwest Medical University

  collaborator OTHER

• Huashan Hospital

  lead OTHER

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-02-10

Primary Completion

2022-08-20

Completion

2022-12-20

Countries

• China

Study Locations